Cargando…

Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III

PURPOSE: Polyglandular autoimmune syndromes (PAS) are complex, heterogeneous disorders in which various autoimmune diseases can occur, affecting both endocrine and non-endocrine organs. In this meta-analysis, the prevalence of associated autoimmune disorders was investigated in PAS II and III. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham-Dobor, G., Hanák, L., Hegyi, P., Márta, K., Párniczky, A., Gergics, M., Sarlós, P., Erőss, B., Mezősi, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431444/
https://www.ncbi.nlm.nih.gov/pubmed/32227311
http://dx.doi.org/10.1007/s40618-020-01229-1
_version_ 1783571581138632704
author Pham-Dobor, G.
Hanák, L.
Hegyi, P.
Márta, K.
Párniczky, A.
Gergics, M.
Sarlós, P.
Erőss, B.
Mezősi, E.
author_facet Pham-Dobor, G.
Hanák, L.
Hegyi, P.
Márta, K.
Párniczky, A.
Gergics, M.
Sarlós, P.
Erőss, B.
Mezősi, E.
author_sort Pham-Dobor, G.
collection PubMed
description PURPOSE: Polyglandular autoimmune syndromes (PAS) are complex, heterogeneous disorders in which various autoimmune diseases can occur, affecting both endocrine and non-endocrine organs. In this meta-analysis, the prevalence of associated autoimmune disorders was investigated in PAS II and III. METHODS: A comprehensive search in MEDLINE and Embase databases identified 479 studies with the keywords of PAS II and PAS III. 18 records containing a total of 1312 patients fulfilled our inclusion criteria (original studies reporting at least 10 cases and containing the combination of other autoimmune disorders) and were selected for further analysis. A meta-analysis of prevalence was performed using the random-effects model with the calculation of 95% confidence intervals (CI). Results of each meta-analysis were displayed graphically using forest plots. RESULTS: Distinction between PAS II and PAS III was made in 842 cases, of which 177 and 665 were PAS II and III (21.1 vs 78.9%), respectively. The prevalence of Hashimoto’s thyroiditis was significantly higher than that of Graves’s disease (39% [95% CI 17–65%] vs. 4% [95% CI 0–10%], respectively; p = 0.001). In PAS II, Addison’s disease (AD) coexisted with AITDs, T1DM or the combination of these conditions in 65, 18 and 10% of cases, respectively. In addition, one other endocrine and five non-endocrine organ-specific autoimmune disorders were reported. In PAS III, two other autoimmune endocrinopathies, six non-endocrine organ-specific, and four systemic autoimmune disorders were found in combination with AITDs. CONCLUSIONS: AITDs, T1DM and AD are the most common combinations in PAS, thus screening for these conditions seems to be reasonable. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40618-020-01229-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7431444
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74314442020-08-19 Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III Pham-Dobor, G. Hanák, L. Hegyi, P. Márta, K. Párniczky, A. Gergics, M. Sarlós, P. Erőss, B. Mezősi, E. J Endocrinol Invest Original Article PURPOSE: Polyglandular autoimmune syndromes (PAS) are complex, heterogeneous disorders in which various autoimmune diseases can occur, affecting both endocrine and non-endocrine organs. In this meta-analysis, the prevalence of associated autoimmune disorders was investigated in PAS II and III. METHODS: A comprehensive search in MEDLINE and Embase databases identified 479 studies with the keywords of PAS II and PAS III. 18 records containing a total of 1312 patients fulfilled our inclusion criteria (original studies reporting at least 10 cases and containing the combination of other autoimmune disorders) and were selected for further analysis. A meta-analysis of prevalence was performed using the random-effects model with the calculation of 95% confidence intervals (CI). Results of each meta-analysis were displayed graphically using forest plots. RESULTS: Distinction between PAS II and PAS III was made in 842 cases, of which 177 and 665 were PAS II and III (21.1 vs 78.9%), respectively. The prevalence of Hashimoto’s thyroiditis was significantly higher than that of Graves’s disease (39% [95% CI 17–65%] vs. 4% [95% CI 0–10%], respectively; p = 0.001). In PAS II, Addison’s disease (AD) coexisted with AITDs, T1DM or the combination of these conditions in 65, 18 and 10% of cases, respectively. In addition, one other endocrine and five non-endocrine organ-specific autoimmune disorders were reported. In PAS III, two other autoimmune endocrinopathies, six non-endocrine organ-specific, and four systemic autoimmune disorders were found in combination with AITDs. CONCLUSIONS: AITDs, T1DM and AD are the most common combinations in PAS, thus screening for these conditions seems to be reasonable. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40618-020-01229-1) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-08-17 2020 /pmc/articles/PMC7431444/ /pubmed/32227311 http://dx.doi.org/10.1007/s40618-020-01229-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Pham-Dobor, G.
Hanák, L.
Hegyi, P.
Márta, K.
Párniczky, A.
Gergics, M.
Sarlós, P.
Erőss, B.
Mezősi, E.
Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III
title Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III
title_full Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III
title_fullStr Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III
title_full_unstemmed Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III
title_short Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III
title_sort prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type ii and iii
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431444/
https://www.ncbi.nlm.nih.gov/pubmed/32227311
http://dx.doi.org/10.1007/s40618-020-01229-1
work_keys_str_mv AT phamdoborg prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii
AT hanakl prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii
AT hegyip prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii
AT martak prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii
AT parniczkya prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii
AT gergicsm prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii
AT sarlosp prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii
AT erossb prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii
AT mezosie prevalenceofotherautoimmunediseasesinpolyglandularautoimmunesyndromestypeiiandiii